i
Novel Treatment of a Vaccinia Virus Infection from an Occupational Needlestick — San Diego, California, 2019
-
October 25 2019
Source: MMWR Morb Mortal Wkly Rep. 68(42):943-946
Details:
-
Alternative Title:MMWR Morb Mortal Wkly Rep
-
Personal Author:
-
Description:Vaccinia virus (VACV) is an orthopoxvirus used in smallpox vaccines, as a vector for novel cancer treatments, and for experimental vaccine research (1). The Advisory Committee on Immunization Practices (ACIP) recommends smallpox vaccination for laboratory workers who handle replication-competent VACV (1). For bioterrorism preparedness, the U.S. government stockpiles tecovirimat, the first Food and Drug Administration-approved antiviral for treatment of smallpox (caused by variola virus and globally eradicated in 1980*|) (2). Tecovirimat has activity against other orthopoxviruses and can be administered under a CDC investigational new drug protocol. CDC was notified about an unvaccinated laboratory worker with a needlestick exposure to VACV, who developed a lesion on her left index finger. CDC and partners performed laboratory confirmation, contacted the study sponsor to identify the VACV strain, and provided oversight for the first case of laboratory-acquired VACV treated with tecovirimat plus intravenous vaccinia immunoglobulin (VIGIV). This investigation highlights 1) the misconception among laboratory workers about the virulence of VACV strains; 2) the importance of providing laboratorians with pathogen information and postexposure procedures; and 3) that although tecovirimat can be used to treat VACV infections, its therapeutic benefit remains unclear.
-
Subject:
-
Pubmed ID:31647789
-
Pubmed Central ID:PMC6812835
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
File Type: